phrykt

Ptc Therapeutics, Inc. (PTCT): who owns it and who trades it

As of Nov 16, 2026, PTCT insiders reported 202 open-market sales worth $56.2M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Neil Gregory Almstead (CHIEF TECHNICAL OPS OFFI), with $22.4M. 7 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling PTC Therapeutics

From the latest filings

Overall: more buying than selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PTCT

380 funds and institutions reported PTCT shares worth $8.2B at the end of Q2 2026. The largest holder is BlackRock, Inc. with $1.1B.

10 largest owners, by value

BlackRock, Inc.$1.1B
Rtw Investments, LP$632M
Jupiter Topco LLC$590M
Vanguard Portfolio Management LLC$402M
State Street Corp$375M
Wellington Management Group LLP$337M
Vanguard Capital Management LLC$305M
Geode Capital Management, LLC$180M
Toronto Dominion Bank$177M
Westfield Capital Management Co LP$160M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.13.96M–$1.1B+8%
Rtw Investments, LP7.75M–$632MNo change
Jupiter Topco LLC7.24M–$590M–
Vanguard Portfolio Management LLC4.93M–$402M+3%
State Street Corp4.60M–$375M+6%
Wellington Management Group LLP4.13M–$337M+5%
Vanguard Capital Management LLC3.74M–$305M+2%
Geode Capital Management, LLC2.21M–$180M-0%
Toronto Dominion Bank2.17M–$177M-28%
Westfield Capital Management Co LP1.96M–$160M–
Hood River Capital Management LLC1.74M–$142M+4%
William Blair Investment Management, LLC1.72M–$141M–
D. E. Shaw & Co., Inc.1.55M–$126M-6%
Tang Capital Management LLC1.50M–$122MNo change
Bank of America Corp1.45M–$118M-23%
Driehaus Capital Management LLC1.44M–$117M+42%
FMR LLC (Fidelity)1.40M–$114M-9%
Jefferies Financial Group Inc.1.36M–$111M+0%
Fuller & Thaler Asset Management, Inc.1.16M–$94.4M–
Pictet Asset Management Holding SA1.15M–$93.6M-3%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, PTCT insiders reported $0 of open-market purchases and $56.2M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$56.2M
202 trades, 13 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Oct 14, 2026
Filed Oct 16, 2026

Purchases and sales by month

$8.8M$8.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 14, 2026Michael SchmertzlerDirectorSale plan2,118$59.52$126KForm 4
Oct 14, 2026Michael SchmertzlerDirectorSale plan382$60.14$23KForm 4
Oct 9, 2026Mark Elliott BouldingVice presidentSale plan192$64.26$12.3KForm 4
Oct 7, 2026Michael SchmertzlerDirectorSale plan2,447$63.38$155KForm 4
Oct 7, 2026Michael SchmertzlerDirectorSale plan53$63.95$3.4KForm 4
Oct 6, 2026Mark Elliott BouldingVice presidentSale plan435$64.16$27.9KForm 4
Oct 5, 2026Mark Elliott BouldingVice presidentSale plan1,638$64.03$105KForm 4
Sep 30, 2026Glenn Jr Md Phd SteeleDirectorSale plan12,000$65.16$782KForm 4
Sep 17, 2026Michael SchmertzlerDirectorSale plan376$68.45$25.7KForm 4
Sep 17, 2026Michael SchmertzlerDirectorSale plan9,624$67.83$653KForm 4
Sep 16, 2026Michael SchmertzlerDirectorSale plan2,994$66.58$199KForm 4
Sep 16, 2026Michael SchmertzlerDirectorSale plan7,006$67.35$472KForm 4
Sep 10, 2026Michael SchmertzlerDirectorSale plan10,000$67.34$673KForm 4
Sep 9, 2026Michael SchmertzlerDirectorSale plan9,428$67.79$639KForm 4
Sep 9, 2026Michael SchmertzlerDirectorSale plan572$68.67$39.3KForm 4
Aug 27, 2026Michael SchmertzlerDirectorSale plan610$72.22$44.1KForm 4
Aug 27, 2026Michael SchmertzlerDirectorSale plan11,890$71.55$851KForm 4
Aug 26, 2026Michael SchmertzlerDirectorSale plan6,874$72.74$500KForm 4
Aug 26, 2026Michael SchmertzlerDirectorSale plan5,626$73.18$412KForm 4
Aug 20, 2026Michael SchmertzlerDirectorSale plan691$72.92$50.4KForm 4
Aug 20, 2026Michael SchmertzlerDirectorSale plan2,390$71.88$172KForm 4
Aug 20, 2026Michael SchmertzlerDirectorSale plan9,419$70.78$667KForm 4
Aug 19, 2026Michael SchmertzlerDirectorSale plan5,335$72.86$389KForm 4
Aug 19, 2026Michael SchmertzlerDirectorSale plan7,165$73.67$528KForm 4
Aug 17, 2026Mark Elliott BouldingVice presidentSale plan969$72.90$70.6KForm 4
Aug 17, 2026Mark Elliott BouldingVice presidentSale plan1,844$72.39$133KForm 4
Aug 4, 2026Matthew B. KleinCEOSale plan10,292$68.57$706KForm 4
Jul 14, 2026Pierre GravierCFOSale plan3,494$80.35$281KForm 4
Jul 9, 2026Mary L. SmithDirectorSale plan5,834$90.00$525KForm 4
Jul 9, 2026Mary L. SmithDirectorSale plan10,000$90.00$900KForm 4
Jul 9, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan2,464$90.25$222KForm 4
Jul 7, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan9,288$89.44$831KForm 4
Jul 7, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan11,369$89.03$1MForm 4
Jul 7, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan3,956$87.17$345KForm 4
Jul 6, 2026Mark Elliott BouldingVice presidentSale plan833$84.41$70.3KForm 4
Jul 6, 2026Mark Elliott BouldingVice presidentSale plan313$83.10$26KForm 4
Jul 6, 2026Mark Elliott BouldingVice presidentSale plan745$86.38$64.4KForm 4
Jul 6, 2026Mark Elliott BouldingVice presidentSale plan519$85.84$44.6KForm 4
Jul 6, 2026Mark Elliott BouldingVice presidentSale plan1,036$84.41$87.4KForm 4
Jul 6, 2026Mark Elliott BouldingVice presidentSale plan387$83.10$32.2KForm 4
Jul 6, 2026Mark Elliott BouldingVice presidentSale plan601$86.38$51.9KForm 4
Jul 6, 2026Mark Elliott BouldingVice presidentSale plan645$85.84$55.4KForm 4
Jul 6, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan385$86.34$33.2KForm 4
Jul 6, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan426$85.28$36.3KForm 4
Jul 6, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan2,474$87.03$215KForm 4
Jul 6, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan8,786$85.35$750KForm 4
Jul 6, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan10,090$86.32$871KForm 4
Jun 26, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan412$85.23$35.1KForm 4
Jun 26, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan7,718$85.26$658KForm 4
Jun 25, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan419$86.39$36.2KForm 4
Jun 25, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan8,522$85.26$727KForm 4
Jun 25, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan11,337$86.51$981KForm 4
Jun 25, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan100$87.00$8.7KForm 4
Jun 25, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan582$85.24$49.6KForm 4
Jun 24, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan401$85.01$34.1KForm 4
Jun 24, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan4,922$85.03$419KForm 4
Jun 22, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan11,619$81.21$944KForm 4
Jun 22, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan12,130$80.61$978KForm 4
Jun 17, 2026Christine Marie UtterVice presidentSale plan19,686$75.56$1.5MForm 4
Jun 17, 2026Mark Elliott BouldingVice presidentSale plan1,850$79.24$147KForm 4
Jun 17, 2026Mark Elliott BouldingVice presidentSale plan1,703$78.50$134KForm 4
Jun 17, 2026Mark Elliott BouldingVice presidentSale plan309$79.25$24.5KForm 4
Jun 17, 2026Mark Elliott BouldingVice presidentSale plan6,600$78.50$518KForm 4
Jun 10, 2026Eric PauwelsCHIEF BUSINESS OFFICERSale plan3,711$75.00$278KForm 4
Jun 10, 2026Eric PauwelsCHIEF BUSINESS OFFICERSale plan17,566$75.00$1.3MForm 4
May 15, 2026Mark Elliott BouldingVice presidentSale plan456$72.67$33.1KForm 4
May 15, 2026Mark Elliott BouldingVice presidentSale plan2,356$72.08$170KForm 4
May 14, 2026Matthew B. KleinCEOSale plan7,221$73.08$528KForm 4
May 14, 2026Matthew B. KleinCEOSale plan679$73.06$49.6KForm 4
May 14, 2026Matthew B. KleinCEOSale plan2,100$73.08$153KForm 4
May 14, 2026Matthew B. KleinCEOSale plan2,572$72.46$186KForm 4
May 8, 2026Mark Elliott BouldingVice presidentSale plan840$78.23$65.7KForm 4
May 8, 2026Mark Elliott BouldingVice presidentSale plan1,900$79.31$151KForm 4
May 8, 2026Mark Elliott BouldingVice presidentSale plan200$78.00$15.6KForm 4
May 8, 2026Mark Elliott BouldingVice presidentSale plan600$79.28$47.6KForm 4
Apr 21, 2026Matthew B. KleinCEOSale plan2,850$70.91$202KForm 4
Apr 6, 2026Mark Elliott BouldingVice presidentSale plan822$68.91$56.6KForm 4
Apr 6, 2026Mark Elliott BouldingVice presidentSale plan1,443$69.75$101KForm 4
Apr 2, 2026Lee Scott GoldenVice presidentSale plan829$67.99$56.4KForm 4
Apr 1, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan39,393$68.89$2.7MForm 4
Apr 1, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan80$70.30$5.6KForm 4
Apr 1, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan12,530$69.50$871KForm 4
Mar 12, 2026Matthew B. KleinCEOSale plan2,662$64.08$171KForm 4
Mar 10, 2026Stephanie OkeyDirectorSale plan1,167$70.00$81.7KForm 4
Mar 10, 2026Stephanie OkeyDirectorSale plan14,000$70.00$980KForm 4
Mar 5, 2026Stephanie OkeyDirectorSale plan6,333$63.38$401KForm 4
Mar 5, 2026Lee Scott GoldenVice presidentSale plan10,000$63.38$634KForm 4
Mar 5, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan3,989$63.38$253KForm 4
Feb 19, 2026Mark Elliott BouldingVice presidentSale plan590$69.82$41.2KForm 4
Feb 19, 2026Mark Elliott BouldingVice presidentSale plan212$68.54$14.5KForm 4
Feb 19, 2026Mark Elliott BouldingVice presidentSale plan1,629$69.82$114KForm 4
Feb 19, 2026Mark Elliott BouldingVice presidentSale plan588$68.54$40.3KForm 4
Feb 18, 2026Christine Marie UtterVice presidentSale plan2,494$69.36$173KForm 4
Feb 18, 2026Pierre GravierCFOSale plan2,992$69.36$208KForm 4
Feb 18, 2026Eric PauwelsCHIEF BUSINESS OFFICERSale plan3,019$69.36$209KForm 4
Feb 18, 2026Matthew B. KleinCEOSale plan7,371$69.36$511KForm 4
Feb 18, 2026Lee Scott GoldenVice presidentSale plan2,484$69.36$172KForm 4
Feb 18, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan3,056$69.36$212KForm 4
Feb 18, 2026Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFISale plan65$69.36$4.5KForm 4
Feb 18, 2026Mark Elliott BouldingVice presidentSale plan3,081$69.36$214KForm 4

Latest 100 of 202 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER–$22.4MJul 9, 2026
Eric PauwelsCHIEF BUSINESS OFFICER–$7.5MJun 10, 2026
Michael SchmertzlerDirector–$6.6MOct 14, 2026
Mark Elliott BouldingEXEC. VP AND CLO–$4.2MOct 9, 2026
Matthew B. KleinCHIEF EXECUTIVE OFFICER, Director–$4.2MAug 4, 2026
Allan Steven JacobsonDirector–$2.1MNov 25, 2025
Christine Marie UtterSVP, CHIEF ACCOUNTING OFFICER–$1.9MJun 17, 2026
Glenn Jr Md Phd SteeleDirector–$1.7MSep 30, 2026
Stephanie OkeyDirector–$1.5MMar 10, 2026
Mary L. SmithDirector–$1.4MJul 9, 2026
Lee Scott GoldenEVP & CHIEF MEDICAL OFFICER–$1.1MApr 2, 2026
Emma ReeveDirector–$908KJan 5, 2026
Pierre GravierCHIEF FINANCIAL OFFICER–$653KJul 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PTCT short interest

Moderate short interest. 9.3% of PTCT shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 24%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 7.78M PTCT shares were sold short, 9.3% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 1.04M shares, buying them all back would take about 7.5 trading days (days to cover).

Shares short, % of all shares

9.31%Jul 31Oct 3013.2%

Days to cover

7.5May 15Oct 3013.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20267.78M9.31%-6%1.04M7.5
Oct 15, 20268.30M9.95%-9%1.09M7.6
Sep 30, 20269.17M10.99%-6%1.49M6.1
Sep 15, 20269.74M11.67%-1%882,76211.0
Aug 31, 20269.83M11.78%-4%809,90912.1
Aug 14, 202610.22M12.25%-3%944,36110.8
Jul 31, 202610.57M12.66%+7%1.40M7.5
Jul 15, 20269.83M–-43%2.07M4.8
Jun 30, 202617.32M–+47%3.23M5.4
Jun 15, 202611.78M–+10%1.51M7.8
May 29, 202610.67M–+4%963,23111.1
May 15, 202610.24M–+5%1.71M6.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

PTC Therapeutics company events

PTC Therapeutics filed 17 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026AnnouncementShared information with investors. Filing
  2. Oct 29, 2026ResultsReleased financial results. Filing
  3. Sep 21, 2026AnnouncementShared information with investors. Filing
  4. Aug 28, 2026AgreementPTC Therapeutics, Inc. entered into an asset purchase agreement with Sangamo Therapeutics, Inc., pursuant to which the Company agreed to acquire from Sangamo, subject to the terms and conditions set forth in the Asset Purchase Agreement, all of Sangamo ’s right, title and interest in and to the… Filing
  5. Aug 13, 2026AnnouncementThe Company issued a press release in which it announced the planned Acquisition. Filing
  6. Jul 30, 2026LeadershipThe Company appointed Hege Sollie-Zetlmayer to its board of directors, effective immediately, filling a vacancy on the Board. Filing
  7. Jun 18, 2026AgreementPTC Therapeutics, Inc. completed its previously announced private offering of $550 million of its 0.0% Convertible Senior Notes due 2031 and entered into an indenture with U.S. Bank Trust Company, National Association, as trustee, governing the Notes. Filing
  8. Jun 16, 2026AnnouncementPTC Therapeutics, Inc. issued a press release announcing the pricing of its previously announced offering of $500.0 million of 0.00% Convertible Senior Notes due 2031. Filing
  9. Jun 9, 2026LeadershipAlethia Young, a member of the board of directors of PTC Therapeutics, Inc., notified the Company of her resignation from the Board effective June 8, 2026. Filing
  10. Jun 5, 2026VoteReported shareholder vote results. Filing
  11. May 7, 2026ResultsReleased financial results. Filing
  12. Apr 28, 2026AnnouncementShared information with investors. Filing
  13. Mar 25, 2026LeadershipPTC Therapeutics, Inc., appointed Jessica Chutter to its board of directors, effective immediately, filling a vacancy on the Board. Filing
  14. Feb 19, 2026ResultsReleased financial results. Filing
  15. Feb 12, 2026AnnouncementShared information with investors. Filing
  16. Jan 12, 2026ResultsReleased financial results. Filing
  17. Dec 29, 2025AgreementPTC Therapeutics, Inc., Royalty Pharma Investments 2019 ICAV, and, for the limited purposes set forth in the Purchase Agreement (as defined below), Royalty Pharma plc, entered into an Amendment No. 2 to Amended and Restated Royalty Purchase Agreement, which amends that certain Amended and Restated… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

PTC Therapeutics financials

Famous investors that hold PTCT

7 of the 50 well-known investors we track reported holding PTCT in their latest 13F filing. The largest position is Steve Cohen's, worth $91.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20261.41M$91.3M0.2%New
Jim Simons · Renaissance TechnologiesQ3 2026787,100$51M0.1%+9%
Ken Griffin · Citadel AdvisorsQ3 2026427,252$27.7M0.0%-43%
Ray Dalio · Bridgewater AssociatesQ3 2026145,446$9.4M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 2026117,809$7.6M0.0%+757%
Ken Fisher · Fisher Asset ManagementQ3 202643,083$2.8M0.0%+6%
Israel Englander · Millennium ManagementQ3 202637,580$2.4M0.0%-19%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named PTCT in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Wellington Management Group LLP13G6.3%
Nov 16, 2026Wellington Management Group LLP13G6.3%
Nov 16, 2026RTW Investments, LP13G/A1.9%
Nov 16, 2026RTW Investments, LP13G/A1.9%
Nov 10, 2026STATE STREET CORPORATION13G6.6%
Nov 10, 2026STATE STREET CORPORATION13G6.6%

Questions about Ptc Therapeutics, Inc. (PTCT) stock

Who owns the most PTCT stock?

The largest reported owner of Ptc Therapeutics, Inc. (PTCT) is BlackRock, Inc.. In total, 380 funds and institutions reported holding PTCT at the end of Q2 2026. See the largest owners.

Are PTCT insiders buying or selling?

In the last 12 months, PTCT insiders reported no open-market purchases and 202 sales worth $56.2M. The latest trade was on Oct 14, 2026. See every trade.

What is the short interest in PTCT?

As of Oct 30, 2026, 7.78M PTCT shares were sold short, 9.3% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 1.04M shares, buying them all back would take about 7.5 trading days (days to cover). See the history.

Which famous investors hold PTCT?

7 of the 50 well-known investors we track reported PTCT in their latest 13F filing, including Steve Cohen, Jim Simons, Ken Griffin. The largest position is worth $91.3M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.